> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Aurobindo Recalls Lots with NDEA Contamination
- URL: https://www.fdaweb.com/aurobindo-recalls-lots-with-ndea-contamination/
- Published: 2019-01-02T12:00:00.000Z
- Updated: 2026-09-15T00:51:24.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5143065

FDA says Aurobindo Pharma has recalled two lots of valsartan tablets, 26 lots of amlodipine and valsartan combination tablets, and 52 lots of valsartan and hydrochlorothiazide combination tablets due to the amount of N-Nitrosodiethylamine (NDEA) in the valsartan active pharmaceutical ingredient. The agency [notice](http://app.info.fda.gov/e/es?s=2027422842&e=175417&elqTrackId=78D8A052C380BCBFF284D754BEBE9730&elq=33e6e09489d54b009f38f8d6d2c1e4d9&elqaid=6428&elqat=1&ref=fdaweb.com) says that Aurobindo is recalling amlodipine and hydrochlorothiazide only in combination medications containing valsartan. Neither amlodipine nor hydrochlorothiazide is under recall by itself, it says.